Sector News

Pharmaceutical giant Merck picks London for new HQ

November 27, 2017
Life sciences

Pharmaceutical giant Merck has chosen central London as the site of its new headquarters.

The company’s hub will be home to 150 new researchers, and 800 additional staff. Merck’s other European clinical operations will also move to the site from the company’s current headquarters in Hoddesdon, Hertfordshire.

The American pharmaceutical business has started to look at possible locations for the centre, which is set to open in 2020. Merck said it chose London because the city will facilitate its work with researchers both in the UK and in Europe.

“We believe London to be a unique bioscience centre of excellence and a key component of the established golden triangle for academic science of London-Oxford-Cambridge,” said Louise Houson, managing director, Merck in the UK and Ireland.

Merck chose London as part of a life sciences sector deal with the government.

The government will announce four such sector deals today along with its Industrial Strategy White Paper. Other deals have been struck with the construction, artificial intelligence and automotive industries.

The new partnerships with the government are backed by co-investment from the private sector.

Business Secretary Greg Clark said: “We are an open, flexible economy, built on trade and engagement with the world. We have a competitive business environment with a deserved reputation for being a dependable and confident place to do business, thanks to our high standards, respected institutions and a reliable rule of law.”

The Industrial Strategy will also seek to fix the UK’s productivity problems, Clark said.

By Helen Cahill

Source: City AM

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.